Quince Therapeutics, Inc.
QNCX
$0.9905
-$0.0095-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.08M | 15.91M | 16.94M | 16.47M | 15.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.67M | 31.90M | 29.45M | 26.19M | 24.58M |
| Operating Income | -33.67M | -31.90M | -29.45M | -26.19M | -24.58M |
| Income Before Tax | -56.74M | -53.13M | -53.01M | -30.20M | -31.58M |
| Income Tax Expenses | 87.00K | 131.00K | 118.00K | 82.00K | -197.00K |
| Earnings from Continuing Operations | -56.83 | -53.26 | -53.12 | -30.28 | -31.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.83M | -53.26M | -53.12M | -30.28M | -31.39M |
| EBIT | -33.67M | -31.90M | -29.45M | -26.19M | -24.58M |
| EBITDA | -33.48M | -31.43M | -29.06M | -25.85M | -24.26M |
| EPS Basic | -1.31 | -1.25 | -1.27 | -0.76 | -0.84 |
| Normalized Basic EPS | -0.48 | -0.44 | -0.41 | -0.38 | -0.37 |
| EPS Diluted | -1.31 | -1.25 | -1.27 | -0.76 | -0.84 |
| Normalized Diluted EPS | -0.48 | -0.44 | -0.41 | -0.38 | -0.37 |
| Average Basic Shares Outstanding | 173.05M | 170.40M | 163.30M | 156.13M | 148.97M |
| Average Diluted Shares Outstanding | 173.05M | 170.40M | 163.30M | 156.13M | 148.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |